Clinical trials combining MET inhibitors together with irreversible ERBB inhibitors have been discussed for lung cancer and colorectal cancer39,40, and a recent publication has also investigated the use of MET inhibitor foretinib with EGFR inhibitor gefitinib or lapatinib in CMM cell lines41. Here, EGFR is linked to lung carcinoma.